According to the Zhitong Finance App, Tengsheng Pharmaceutical-B (02137.HK) announced that the company launched a self-developed BriSC™ (Bispecific RNAi Silencing, double specific RNA interference silencing) low-interfering ribonucleic acid (siRNA) drug development platform to promote the development of next-generation ribonucleic acid (RNA) therapies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.